"use client";
import React from 'react';
import Image from 'next/image';
import { Icon } from './common.jsx';

const START_URL = "https://go.telehealthfx.com/start";

function BlogGLP1ForPCOS() {
  return (
    <>
      <section className="section" style={{ minHeight: '60vh', paddingTop: 120 }}>
      <div className="container" style={{ maxWidth: 800 }}>
        <div className="eyebrow" style={{ marginBottom: 20 }}>Women's Health</div>
        <h1 className="serif" style={{ fontSize: 56, marginBottom: 24, lineHeight: 1.1 }}>
          GLP-1 for PCOS: <span style={{ fontStyle: 'italic', color: 'var(--brand)' }}>How Semaglutide and Tirzepatide Are Changing Polycystic Ovary Syndrome Treatment</span>
        </h1>
        <div style={{ display: 'flex', alignItems: 'center', gap: 12, marginBottom: 48, paddingBottom: 24, borderBottom: '1px solid var(--line-soft)' }}>
          <div style={{ width: 40, height: 40, borderRadius: '50%', background: 'var(--brand)' }}>
            <Image src="/assets/jm-profile.jpg" alt="Julian Mercer" width={1024} height={1024} style={{ width: '100%', height: '100%', objectFit: 'cover', borderRadius: '50%', height: "auto"}} priority={true} />
          </div>
          <div>
            <div style={{ fontWeight: 500, fontSize: 14 }}><a href="/about" style={{ color: "var(--ink)", textDecoration: "none" }}>Julian Mercer, M.S.</a></div>
            <div style={{ fontSize: 13, color: 'var(--ink-3)' }}>Lead Bio-Systems Analyst · Updated May 2026 · 30 min read</div>
          </div>
        </div>

        <div className="blog-content" style={{ fontSize: 18, lineHeight: 1.7, color: 'var(--ink-2)' }}>
          <Image src="/assets/glp1-pcos-featured.png" alt="GLP-1 medication for PCOS women's hormonal health" width={1024} height={1024} style={{ width: '100%', borderRadius: 16, marginBottom: 40, border: '1px solid var(--line-soft)', background: '#111', height: "auto"}} priority={true} />

          <p>Polycystic ovary syndrome (PCOS) affects approximately <strong>8–13% of women of reproductive age worldwide</strong>, making it the most common endocrine disorder in this population. And at its metabolic core, PCOS is a disease of <strong>insulin resistance</strong>—the same pathology that <a href="/blog/what-is-a-glp-1-medication" style={{ color: 'var(--brand)', fontWeight: 500 }}>GLP-1 medications</a> were designed to treat.</p>

          <p>For decades, metformin was the only meaningful pharmacological intervention for the metabolic dysfunction underlying PCOS. Now, <a href="/medications/semaglutide" style={{ color: 'var(--brand)', fontWeight: 500 }}>semaglutide</a> and <a href="/medications/tirzepatide" style={{ color: 'var(--brand)', fontWeight: 500 }}>tirzepatide</a> are emerging as transformative treatments—not just for the weight management component, but for the entire PCOS symptom constellation: irregular periods, hyperandrogenism, anovulatory infertility, and metabolic syndrome.</p>

          <h2 className="serif" style={{ fontSize: 32, marginTop: 48, marginBottom: 24, color: 'var(--ink)' }}>The Insulin-Androgen Connection</h2>

          <p>PCOS is not simply a reproductive disorder—it is a systemic metabolic condition. The central driver in most cases is <strong>hyperinsulinemia</strong> (chronically elevated insulin levels caused by insulin resistance). Excess insulin directly stimulates ovarian theca cells to produce androgens (testosterone, DHEA-S), creating the cascade of symptoms that define PCOS:</p>
          <ul>
            <li style={{ marginBottom: 8 }}><strong>Hyperandrogenism:</strong> Acne, hirsutism (excess facial/body hair), androgenic alopecia</li>
            <li style={{ marginBottom: 8 }}><strong>Ovulatory dysfunction:</strong> Irregular or absent menstrual cycles, anovulation, infertility</li>
            <li style={{ marginBottom: 8 }}><strong>Metabolic syndrome:</strong> Central obesity, dyslipidemia, elevated fasting glucose, increased cardiovascular risk</li>
            <li style={{ marginBottom: 8 }}><strong>Polycystic ovarian morphology:</strong> Multiple immature follicular cysts visible on ultrasound</li>
          </ul>

          <p>By powerfully reducing insulin resistance and driving significant weight loss, GLP-1 agonists address the <em>root metabolic cause</em> of PCOS rather than just managing individual symptoms.</p>

          <h2 className="serif" style={{ fontSize: 32, marginTop: 48, marginBottom: 24, color: 'var(--ink)' }}>Clinical Evidence: GLP-1 Agonists for PCOS</h2>

          <p>While GLP-1 agonists are not yet FDA-approved specifically for PCOS, a growing body of clinical trials demonstrates remarkable efficacy:</p>

          <h3 style={{ fontSize: 24, marginTop: 32, marginBottom: 16, color: 'var(--ink)' }}>Weight Loss and Metabolic Improvement</h3>
          <p>Women with PCOS who are overweight or obese experience disproportionate difficulty losing weight due to the metabolic dysfunction. GLP-1 therapy directly counteracts this. Studies show that semaglutide 2.4mg weekly produces <strong>12–16% body weight loss</strong> in PCOS patients—often more than these women have been able to achieve with any previous intervention. Even a 5–10% weight reduction in PCOS has been shown to restore ovulatory cycles in up to 75% of anovulatory women.</p>

          <h3 style={{ fontSize: 24, marginTop: 32, marginBottom: 16, color: 'var(--ink)' }}>Androgen Reduction</h3>
          <p>By reducing hyperinsulinemia, GLP-1 agonists lower ovarian androgen production. Clinical trials have demonstrated significant reductions in free testosterone and DHEA-S levels, translating to clinical improvements in acne, hirsutism, and hair thinning.</p>

          <h3 style={{ fontSize: 24, marginTop: 32, marginBottom: 16, color: 'var(--ink)' }}>Menstrual Regularity and Fertility</h3>
          <p>Multiple studies have reported restoration of regular menstrual cycles and spontaneous ovulation in women with PCOS-related anovulation after initiating GLP-1 therapy. This has significant implications for fertility—though it also introduces an important safety consideration regarding pregnancy (see our <a href="/blog/glp-1-and-pregnancy-fertility-safety-2026" style={{ color: 'var(--brand)', fontWeight: 500 }}>GLP-1 and pregnancy guide</a>).</p>

          <div className="card" style={{ padding: 40, margin: '48px 0', textAlign: 'center', background: '#FFFDF9', borderColor: 'var(--brand)' }}>
            <h3 className="serif" style={{ fontSize: 28, marginBottom: 16, color: 'var(--ink)' }}>PCOS-Informed Clinical Care</h3>
            <p style={{ marginBottom: 24, fontSize: 16 }}>TelehealthFX provides clinician-guided GLP-1 therapy with specific attention to PCOS-related metabolic, hormonal, and reproductive considerations.</p>
            <a href={START_URL} target="_blank" rel="noopener noreferrer" className="btn btn-primary btn-lg" style={{ display: 'inline-flex', justifyContent: 'center' }}>
              Start Your Evaluation <Icon.Arrow />
            </a>
          </div>

          <h2 className="serif" style={{ fontSize: 32, marginTop: 48, marginBottom: 24, color: 'var(--ink)' }}>GLP-1 vs. Metformin for PCOS</h2>

          <p>Metformin has been the standard metabolic intervention for PCOS for over 20 years. While it remains a valuable tool, GLP-1 agonists offer substantial advantages:</p>

          <div style={{ overflowX: 'auto', margin: '24px 0' }}>
            <table style={{ width: '100%', borderCollapse: 'collapse', fontSize: 16 }}>
              <thead>
                <tr style={{ borderBottom: '2px solid var(--ink)' }}>
                  <th style={{ textAlign: 'left', padding: '12px 16px', fontWeight: 600 }}>Outcome</th>
                  <th style={{ textAlign: 'left', padding: '12px 16px', fontWeight: 600 }}>Metformin</th>
                  <th style={{ textAlign: 'left', padding: '12px 16px', fontWeight: 600 }}>GLP-1 Agonist</th>
                </tr>
              </thead>
              <tbody>
                <tr style={{ borderBottom: '1px solid var(--line-soft)' }}><td style={{ padding: '12px 16px' }}>Weight Loss</td><td style={{ padding: '12px 16px' }}>2–5%</td><td style={{ padding: '12px 16px', fontWeight: 600, color: 'var(--brand)' }}>12–22%</td></tr>
                <tr style={{ borderBottom: '1px solid var(--line-soft)' }}><td style={{ padding: '12px 16px' }}>Insulin Sensitivity</td><td style={{ padding: '12px 16px' }}>Moderate improvement</td><td style={{ padding: '12px 16px', fontWeight: 600, color: 'var(--brand)' }}>Significant improvement</td></tr>
                <tr style={{ borderBottom: '1px solid var(--line-soft)' }}><td style={{ padding: '12px 16px' }}>Androgen Reduction</td><td style={{ padding: '12px 16px' }}>Modest</td><td style={{ padding: '12px 16px', fontWeight: 600, color: 'var(--brand)' }}>Significant</td></tr>
                <tr style={{ borderBottom: '1px solid var(--line-soft)' }}><td style={{ padding: '12px 16px' }}>Ovulation Restoration</td><td style={{ padding: '12px 16px' }}>30–40% of patients</td><td style={{ padding: '12px 16px', fontWeight: 600, color: 'var(--brand)' }}>50–75% (with weight loss)</td></tr>
                <tr><td style={{ padding: '12px 16px' }}>CV Protection</td><td style={{ padding: '12px 16px' }}>Some evidence</td><td style={{ padding: '12px 16px', fontWeight: 600, color: 'var(--brand)' }}>Proven (SELECT trial)</td></tr>
              </tbody>
            </table>
          </div>

          <h2 className="serif" style={{ fontSize: 32, marginTop: 48, marginBottom: 24, color: 'var(--ink)' }}>Complementary Therapies for PCOS</h2>

          <p>Combining GLP-1 therapy with evidence-based complementary interventions can address the full spectrum of PCOS pathology. <a href="/medications/berberine" style={{ color: 'var(--brand)', fontWeight: 500 }}>Berberine</a> provides additional AMPK-mediated insulin sensitization. <a href="/medications/nad" style={{ color: 'var(--brand)', fontWeight: 500 }}>NAD+ therapy</a> supports mitochondrial function during caloric restriction. And resistance training is essential for preserving lean mass—a concern we address in our <a href="/blog/glp-1-muscle-loss-the-hidden-risk-nobodys-talking" style={{ color: 'var(--brand)', fontWeight: 500 }}>GLP-1 muscle loss</a> article and our <a href="/blog/glp-1-and-exercise-how-to-combine-medication-with" style={{ color: 'var(--brand)', fontWeight: 500 }}>exercise combination guide</a>.</p>

          <div className="card" style={{ padding: 40, margin: '48px 0', textAlign: 'center', background: '#FFFDF9', borderColor: 'var(--brand)' }}>
            <div style={{ width: 48, height: 48, borderRadius: '50%', background: 'var(--brand-soft)', color: 'var(--brand)', display: 'flex', alignItems: 'center', justifyContent: 'center', margin: '0 auto 20px' }}><Icon.Check size={24} /></div>
            <h3 className="serif" style={{ fontSize: 28, marginBottom: 16, color: 'var(--ink)' }}>Comprehensive PCOS Support</h3>
            <p style={{ marginBottom: 24, fontSize: 16 }}>GLP-1 therapy, berberine, NAD+, and clinician-guided care—all under one roof. No hidden fees, no guesswork.</p>
            <a href={START_URL} target="_blank" rel="noopener noreferrer" className="btn btn-primary btn-lg" style={{ display: 'inline-flex', justifyContent: 'center' }}>
              Check Your Eligibility <Icon.Arrow />
            </a>
          </div>

          <h2 className="serif" style={{ fontSize: 32, marginTop: 48, marginBottom: 24, color: 'var(--ink)' }}>Frequently Asked Questions</h2>

          <h4 style={{ fontSize: 20, marginTop: 24, marginBottom: 8, color: 'var(--ink)' }}>Can semaglutide help with PCOS-related infertility?</h4>
          <p style={{ marginBottom: 24 }}>Clinical evidence suggests that the weight loss and insulin sensitization from GLP-1 therapy can restore ovulatory cycles in many women with anovulatory PCOS. However, GLP-1 medications must be discontinued before conception due to safety concerns. Use effective contraception during treatment and consult your clinician about timing.</p>

          <h4 style={{ fontSize: 20, marginTop: 24, marginBottom: 8, color: 'var(--ink)' }}>Is GLP-1 therapy FDA-approved for PCOS?</h4>
          <p style={{ marginBottom: 24 }}>No. GLP-1 agonists are FDA-approved for type 2 diabetes and/or chronic weight management. Their use in PCOS is considered off-label. However, given the strong metabolic overlap (insulin resistance, obesity), many endocrinologists and reproductive specialists now prescribe them for PCOS patients who meet BMI criteria.</p>

          <h4 style={{ fontSize: 20, marginTop: 24, marginBottom: 8, color: 'var(--ink)' }}>Will GLP-1 help with PCOS acne and hair growth?</h4>
          <p style={{ marginBottom: 24 }}>Yes, indirectly. By reducing hyperinsulinemia, GLP-1 agonists lower ovarian androgen production. As free testosterone levels decline, androgen-driven symptoms—acne, hirsutism, and androgenic alopecia—typically improve over 3–6 months. Results are more pronounced with greater weight loss.</p>

          <div style={{ padding: 40, marginTop: 60, borderRadius: 20, background: 'var(--ink)', color: '#FBF8F3', textAlign: 'center' }}>
            <h2 className="serif" style={{ fontSize: 40, marginBottom: 20, color: '#FBF8F3' }}>Take Control of Your PCOS</h2>
            <p style={{ fontSize: 18, opacity: 0.9, marginBottom: 32, maxWidth: 500, margin: '0 auto 32px' }}>Address the root cause of PCOS—not just the symptoms. Clinician-guided GLP-1 therapy designed for your metabolic profile.</p>
            <a href={START_URL} target="_blank" rel="noopener noreferrer" className="btn btn-lg" style={{ background: '#FBF8F3', color: 'var(--ink)', display: 'inline-flex', justifyContent: 'center', width: '100%', maxWidth: 250 }}>
              Get Started <Icon.Arrow />
            </a>
          </div>

          <div style={{ marginTop: 80, paddingTop: 40, borderTop: '1px solid var(--line-soft)', fontSize: 14, color: 'var(--ink-3)' }}>
            <h3 className="serif" style={{ fontSize: 24, marginBottom: 24, color: 'var(--ink)' }}>Academic References &amp; Clinical Citations</h3>
            <ol style={{ paddingLeft: 20, display: 'flex', flexDirection: 'column', gap: 16 }}>
              <li>Teede, H. J., et al. (2023). International evidence-based guideline for the assessment and management of polycystic ovary syndrome. <em>Human Reproduction</em>, 38(9), 1655–1679. <a href="https://doi.org/10.1093/humrep/dead156" target="_blank" rel="noopener noreferrer" style={{ color: 'var(--brand)', textDecoration: 'underline' }}>https://doi.org/10.1093/humrep/dead156</a></li>
              <li>Elkind-Hirsch, K. E., et al. (2022). Effect of liraglutide and metformin on markers of cardiovascular risk, body composition, and reproductive parameters in women with polycystic ovary syndrome. <em>Fertility and Sterility</em>, 117(3), 622–631. <a href="https://doi.org/10.1016/j.fertnstert.2021.11.013" target="_blank" rel="noopener noreferrer" style={{ color: 'var(--brand)', textDecoration: 'underline' }}>https://doi.org/10.1016/j.fertnstert.2021.11.013</a></li>
              <li>Jensterle, M., et al. (2019). Efficacy of GLP-1 RA compared to metformin in PCOS: A systematic review and meta-analysis. <em>Endocrine Connections</em>, 8(4), 351–362. <a href="https://doi.org/10.1530/EC-19-0046" target="_blank" rel="noopener noreferrer" style={{ color: 'var(--brand)', textDecoration: 'underline' }}>https://doi.org/10.1530/EC-19-0046</a></li>
              <li>Legro, R. S. (2016). Obesity and PCOS: Implications for diagnosis and treatment. <em>Seminars in Reproductive Medicine</em>, 30(6), 496–506. <a href="https://doi.org/10.1055/s-0032-1328878" target="_blank" rel="noopener noreferrer" style={{ color: 'var(--brand)', textDecoration: 'underline' }}>https://doi.org/10.1055/s-0032-1328878</a></li>
            </ol>
          </div>
        </div>
      </div>
    </section>
    </>
  );
}

export { BlogGLP1ForPCOS };
